Mice were sacrificed 1 day or 7 days after treatment and the tumor masses were dissociated and analysed by flow cytometry, distinguishing the immune component (CD45+) from the non-immune component (CD45−) in terms of the percentage of live cells analysed. The gene discussed is PTPRC; the disease is neoplasm.